A phase II study of lapatinib, a dual EGFR and HER-2...

Urologic Oncology: Seminars and Original Investigations 2013 / 1 Vol. 31; Iss. 1

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

Whang, Young E., Armstrong, Andrew J., Rathmell, W. Kimryn, Godley, Paul A., Kim, William Y., Pruthi, Raj S., Wallen, Eric M., Crane, Jeffrey M., Moore, Dominic T., Grigson, Gayle, Morris, Karla, Watk
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Language:
english
Journal:
Urologic Oncology: Seminars and Original Investigations
DOI:
10.1016/j.urolonc.2010.09.018
Date:
January, 2013
File:
PDF, 220 KB
english, 2013
Conversion to is in progress
Conversion to is failed